GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longboard Pharmaceuticals Inc (NAS:LBPH) » Definitions » Cash Flow from Investing

Longboard Pharmaceuticals (Longboard Pharmaceuticals) Cash Flow from Investing : $-212.77 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Longboard Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Longboard Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $255.12 Mil on purchasing investments. It gained $24.20 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Longboard Pharmaceuticals spent $230.92 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Longboard Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for Longboard Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longboard Pharmaceuticals Cash Flow from Investing Chart

Longboard Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
- -40.72 -17.06 24.23

Longboard Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.08 7.96 11.75 -1.56 -230.92

Longboard Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Longboard Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Longboard Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-212.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Longboard Pharmaceuticals  (NAS:LBPH) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Longboard Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Longboard Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Longboard Pharmaceuticals's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Longboard Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Longboard Pharmaceuticals's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Longboard Pharmaceuticals spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Longboard Pharmaceuticals's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Longboard Pharmaceuticals gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Longboard Pharmaceuticals's purchase of investment for the three months ended in Mar. 2024 was $-255.12 Mil. It means Longboard Pharmaceuticals spent {stock_data.stock.currency_symbol}}255.12 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Longboard Pharmaceuticals's sale of investment for the three months ended in Mar. 2024 was $24.20 Mil. It means Longboard Pharmaceuticals gained $24.20 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Longboard Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Longboard Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Longboard Pharmaceuticals's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Longboard Pharmaceuticals paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Longboard Pharmaceuticals's cash from other investing activities for the three months ended in Mar. 2024 was $-0.00 Mil. It means Longboard Pharmaceuticals paid $0.00 Mil for other investing activities.


Longboard Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Longboard Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Longboard Pharmaceuticals (Longboard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4275 Executive Square, Suite 950, La Jolla, CA, USA, 92037
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Executives
Randall Kaye officer: CMO 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Jane Tiller director C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037
Brandi Roberts officer: Chief Financial Officer 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Phillip M Schneider director GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Vincent Aurentz director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Kevin Robert Lind director, officer: President and CEO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Casey Lynch director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Le Goff Corinne director 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Arena Pharmaceuticals Inc 10 percent owner 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Philip Perera officer: Chief Medical Officer C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121